Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis

Neurology

Volumn 81, Issue 20, 2013, Pages 1768-1772

  Henault, David ^a   Galleguillos, Lorna ^a   Moore, Craig ^a   Johnson, Trina ^a   Bar Or, Amit ^a   Antel, Jack ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR7; FINGOLIMOD;

ADULT; ARTICLE; BASAL CELL CARCINOMA; BLOOD SAMPLING; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CRYOPRESERVATION; EFFECTOR CELL; FEMALE; HUMAN; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; SKIN CARCINOMA; T LYMPHOCYTE SUBPOPULATION; TESTIS CANCER;

ADULT; CELL COUNT; CYTOKINES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SPHINGOSINE; T-LYMPHOCYTES;

EID: 84888247060     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000435564.92609.2c     Document Type: Article

References (10)

1. Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011;76(8 suppl 3):S20-S27.
2. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004;18:551-553.
3. Moschovakis GL, Forster R. Multifaceted activities of CCR7 regulate T-cell homeostasis in health and disease. Eur J Immunol 2012;42:1949-1955.
4. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004;44:532-537.
5. Johnson TA, Lapierre Y, Bar-Or A, Antel JP. Distinct properties of circulating CD81 T cells in FTY720-treated patients with multiple sclerosis. Arch Neurol 2010;67:1449-1455.
6. Bourdette D, Gilden D. Fingolimod and multiple sclerosis: four cautionary tales. Neurology 2012;79:1942-1943.
7. Kappos L, Antel JP, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140.
8. Kappos L, Radue EW, O'Connor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
9. Darlington PJ, Touil T, Doucet JS, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 2013;73:341-354.
10. Johnson TA, Evans BL, Durafourt BA, et al. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients. J Immunol 2011;187:570-579.